Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib

Jingran Ji, Anupam Mitra, D. Ross Camidge, Jonathan W. Riess

Research output: Contribution to journalArticlepeer-review

Abstract

• Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination. • Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer.

Original languageEnglish (US)
JournalClinical lung cancer
DOIs
StateAccepted/In press - 2021

Keywords

  • ALK inhibitor resistance
  • ALK mutation
  • MET amplification
  • MET inhibition
  • Non–small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib'. Together they form a unique fingerprint.

Cite this